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Abstract: Accurate glycemic control (AGC) is difficult due to excessive hypoglycemia risk. Stochastic 
TARgeted (STAR) glycemic control forecasts changes in insulin sensitivity to calculate a range of 
glycemic outcomes for an insulin intervention, creating a risk framework to improve safety and 
performance. An improved, simplified STAR framework was developed to reduce light hypoglycemia 
and clinical effort, while improving nutrition rates and performance. Blood glucose (BG) levels are 
targeted to 80 – 145mg/dL, using insulin and nutrition control for 1-3 hour interventions. Insulin changes 
are limited to +3U/hour and nutrition to ±30% of goal rate (minimum 30%). All targets and rate change 
limits are clinically specified and generalizable. Clinically validated virtual trials were run using clinical 
data from 371 patients (39,841hours) from the SPRINT cohort. Cohort and per-patient results are 
compared to clinical SPRINT data. Performance was measured as time within glycemic bands, and safety 
by patients with severe (BG<40mg/dL) and mild (%BG<72mg/dL) hypoglycemia. Pilot trial results from 
the first 10 patients (1,458 hours) are included to support the in-silico findings. In both virtual and 
clinical trials, mild hypoglycemia was below 2% versus 4% for SPRINT. Severe hypoglycemia was 
reduced from 14 (SPRINT) to 6 (STAR), and 0 in the pilot trial. BG results tighter than SPRINT clinical 
data, with 91.6% BG within the specified target (80–145mg/dL) in virtual trials and 89.4% in pilot trials. 
Clinical effort (measurements) was reduced from 16.1/day to 11.8/day (13.5/day in pilot trials). This 
STAR framework provides safe, accurate glycemic control with significant reductions in hypoglycemia 
and clinical effort due to stochastic forecasting of patient variation – a unique risk-based approach. Initial 
pilot trials validate the in silico design methods and resulting protocol, all of which can be generalized to 
suit any given clinical environment. 
Keywords: Decision support and control; Decision support systems for the control of physiological and 
clinical variables 
1. INTRODUCTION 
Stress-induced hyperglycemia is a significant issue in critical 
care, affecting up to 30-50% of patients and increasing 
morbidity and mortality (McCowen et al., 2001, Krinsley, 
2004). Controlling glycemia has proved difficult due to the 
associated risk of hypoglycemia when highly dynamic 
patients are treated with exogenous insulin (Griesdale et al., 
2009). Both extremes, as well as glycemic variability, have 
been independently linked to increased morbidity and 
mortality (Bagshaw et al., 2009, Egi et al., 2006, Krinsley, 
2008), creating a difficult clinical problem safely and 
effectively regulating glycemia to a physiologically and 
clinically safe range. 
Accurate glycemic control (AGC) can mitigate these 
outcomes(Chase et al., 2008b, Van den Berghe et al., 2001), 
but has proven difficult to achieve safely and consistently 
(Casaer et al., 2011). Only one study (Chase et al., 2008b) 
reduced both mortality and hypoglycemia. However, the 
higher nursing workloads due to high density glucose 
readings are impractical in many units (Mackenzie et al., 
2005, Aragon, 2006). Hand-held glucometers are easier for 
measurement, but their larger errors can add additional 
difficulty for some AGC protocols. Finally, clinical 
compliance determines much of the efficacy of any AGC 
method, with quality of glycemic control thus also limited by 
the confidence and compliance of nursing staff (Aragon, 
2006, Chase et al., 2008a). All of these issues interact with 
the inherent inter- and intra- patient metabolic variability 
(Chase et al., 2011) to exacerbate the difficulty of achieving 
good control. Hence, glycemic control targets are often raised 
to mitigate these factors and avoid hypoglycaemia as a best 
outcome compromise, despite the physiological and clinical 
evidence on the negative impact of even moderate 
hyperglycemia (McCowen et al., 2001, Krinsley, 2004). 
Directly quantifying and managing hyperglycemic and 
hypoglycemic risk as a function of inter- and intra- patient 
metabolic variability can leverage AGC benefits and 
minimize risk of unintended harm. STAR (Stochastic 
TARgeted) is a model-based AGC framework that can be 
implemented across a range of clinical scenarios and 
approaches, and uses dynamic and stochastic models to 
regulate BG levels, workload and patient safety within a pre-
defined risk management approach. STAR uses stochastic 
forecasting of a patient's potential metabolic variability(Lin et 
al., 2008) in conjunction with a clinically validated 
mathematical model (Lin et al., 2011, Chase et al., 2010b) to 
determine optimal insulin and nutrition treatment 
  
     
 
combinations with specified risks of moderate hyper- and 
hypo- glycemia. In essence, it is a patient-specific approach 
to manage inter- and intra- patient variability that overlaps 
the glycemic outcome range for a given intervention with a 
clinically specified desired glycemic range. It thus provides 
both control and a clinically specified risk of moderate 
hypoglycemia. Hence, STAR provides a framework of 
models and methods to manage intra- and inter- patient 
variability to mitigate the significant difficulty and risk seen 
in current glycemic control approaches (Griesdale et al., 
2009, Chase et al., 2011). 
This paper presents an enhanced and simplified STAR 
protocol, and its development and optimization using virtual 
trials. Specific focus is placed on reducing mild 
hypoglycemia (BG < 72mg/dl) and its associated risk 
(Bagshaw et al., 2009), while maintaining glycemia in bands 
with the best evidence for improved outcome. Protocol 
simplicity and transparency are optimized to increase 
compliance. 
2. METHODS 
2.1  Model 
The clinically validated Intensive Care Insulin-Nutrition-
Glucose (ICING) metabolic model was used to simulate the 
fundamental metabolic dynamics (Lin et al., 2011). Table I 
lists the population constants of the model defined in 
Equations 1-6. 
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where G(t) [mmol/L] is the total plasma glucose, I(t) [mU/L] 
is the plasma insulin and interstitial insulin is represented by 
Q(t) [mU/L]. Exogenous insulin input is represented by uex(t) 
[mU/min] and endogenous insulin production is estimated 
with uen [mU/min], modeled as a function of plasma glucose 
concentration determined from critical care patients with a 
minimum pancreatic output of 1U/hr. P1 [mmol] represents 
the glucose in the stomach and P2 [mmol] represents glucose 
in the gut. Enteral glucose input is denoted P(t) [mmol/min]. 
2.2  Virtual Patients 
Clinically validated virtual trials (Chase et al., 2010b) were 
carried out using the SPRINT AGC cohort clinical data 
(Chase et al., 2008b) to create virtual patients. Virtual 
patients are created using clinical data to identify an hourly 
treatment-independent insulin sensitivity profile SI(t) (Hann 
et al., 2005), allowing virtual trials to realistically simulate 
patient response to a given (modified) treatment. This 
approach has been clinically validated on independent 
matched cohort data (Chase et al., 2010b) and in several 
AGC trials (Penning et al., 2011, Evans et al., 2011). Patient 
demographics are given in Table II.  
Patients were considered to require AGC once BG > 
7.0mmol/L, and this value was used to determine the 
beginning of a virtual trial. Interruptions in nutrition are 
common for some patients in clinical practice, and are 
incorporated by setting P(t) = 0 mmol/min over the same 
periods they occurred in the clinical data. Equally, clinically 
specified parenteral nutrition (PN) was included in the 
simulations just as it was given clinically. 
2.4  Stochastic Control Method 
STAR provides patient-specific treatment in real time. 
Stochastic forecasting provides a framework for control of 
future outcomes, particularly the mitigation of mild, 
moderate, and severe hypoglycemia. STAR was also 
developed with the intent to use the simplest, most 
TABLE I 
CONSTANTS USED IN SYSTEM MODEL OF EQUATIONS (1)-(6) 
Model 
var. 
Description Numerical value [typical range] 
pG Endogenous glucose clearance 0.006 min-1 
SI Insulin sensitivity [1x10
-7
-1x10-2] 
L/(mU.min)a 
αG 
Saturation of insulin-dependent glucose 
clearance and receptor-bound insulin 
clearance from interstitium 
1/65 L/mU 
d1 
Rate of glucose transfer between the 
stomach and gut -ln(0.5)/20 
d2 Rate of glucose transfer from the gut to the bloodstream -ln(0.5)/100 
Pmax Maximum disposal rate from the gut 6.11 mmol/min 
EGPb 
Basal endogenous glucose production 
(unsuppressed by glucose and insulin 
concentration) 
1.16 mmol/min 
typically 
CNS Non-insulin mediated glucose uptake by the central nervous system 0.3 mmol/min 
VG Glucose distribution volume 13.3 L 
nI, nC 
Rate of transport between plasma and 
interstitial insulin compartments 0.0075 min
-1 
αI 
Saturation of plasma insulin clearance by 
the liver 1.7x10
-3
 L/mU 
VI Insulin distribution volume 4.0 L 
xL First-pass hepatic insulin clearance 0.67 
nK 
Clearance of insulin from plasma via the 
renal route 0.0542 min
-1 
nL 
Clearance of insulin from plasma via the 
hepatic route 0.1578 min
-1 
aInsulin sensitivity (SI) is identified from clinical data in the range shown. 
 
TABLE II 
PATIENT DEMOGRAPHICS 
 SPRINT cohort 
Total patients 371 
Age (years) 65 [49 – 74] 
% Male 63.6% 
APACHE II score 18 [15 – 24] 
APACHE II risk of death 25.7% [13.1% - 49.4%] 
Diabetic history 62 (16.7%) 
   
 
  
     
 
transparent control logic (Chase et al., 2008a). This latter 
aspect had the goal of ensuring its choices were as 
understandable as possible, and thus directly translated into 
safe, effective and clinically acceptable treatment 
recommendations to maximize compliance. 
When a BG measurement is entered, the model is used to 
evaluate current patient insulin sensitivity (Hann et al., 2005) 
and its likely variation (Lin et al., 2008) over the next 1 to 3 
hours. Insulin is administered in bolus form for safety from 
unintended delays (Lonergan et al., 2006). However, 
infusions may also be used. Robustness to glucometer 
measurement error limits increases in insulin rate to 
+2U/hour, with upper limits on the total bolus dose (6U/hr) 
and any added infusion rate for highly resistant patients 
(3U/hr). Thus, total insulin is limited to 9U/hr. Insulin can be 
reduced to 0U/hr from any rate if required. Enteral nutrition 
is controlled between 30-100% of ACCP goal (Cerra et al., 
1997), and changes are limited to ±30% per intervention 
cycle. However, nutrition administration can be set to a fixed 
constant rate or zero if clinically specified. 
Measurement or treatment interval is specifically limited 
when: 1) current measured BG is outside the specified target 
range of 80-145mg/dL (1-hourly limits); or 2) the patient is 
unable to be fed (2-hourly maximum interval). Otherwise, 
when the current measured BG is within the clinically 
specified target range, STAR calculates intervention options 
(insulin and nutrition) for 1, 2 and 3 hourly measurement 
intervals, and nurses choose from these intervals.  
For each allowed insulin/nutrition combination and treatment 
interval based on the limits specified, stochastic forecasts are 
generated for the predicted 5th percentile of BG outcomes 
(Figure 1, points A, B and C) and the predicted 95th 
percentile of BG outcomes (Figure 1, points D, E and F). For 
all treatment intervals, glycemic level is controlled by 
targeting the 5th percentile of BG outcomes to the lower limit 
of the desired range including tolerance (80-85mg/dL). 
Hypoglycemia is thus directly managed as insulin rates 
cannot be recommended if the predicted 5th percentile is 
below this limit. The tolerance on the lower limit ensures 
consistent interventions between measurement intervals 
offered (1, 2 and 3-hourly). The 5th percentile target is 
prioritized for control due to the skewed nature of the BG 
outcome distribution, as depicted in Figure 1, which ensures 
BG outcomes best overlap the lower (80 - 125mg/dL) desired 
portion of the 80 - 145mg/dL range. This 80 - 125mg/dL 
range is associated with better outcomes (Egi et al., 2006, 
Van den Berghe et al., 2001) and is also associated with 
reduced rate and severity of organ failure (Chase et al., 
2010a). 
Tightness of the AGC provided by STAR is thus determined 
by the treatment of the 95th percentile forecast outcomes. 
This upper limit is used to restrict treatment interval only if a 
desired 2- or 3- hourly treatment allows 95th percentile BG 
above the target range. Monitoring the likelihood of predicted 
BG outcome, as shown in Figure 1, allows for more explicit 
direct control over intra-patient variability and therefore 
directly limits the risk and occurrence of mild hyperglycemia. 
Hourly measurements are always offered, regardless of the 
95th percentile forecast. If the 5th percentile BG is forecast to 
be within tolerance of the target band lower limit the 
treatment is considered acceptable. For cases where the 
forecast BG range does not meet this criteria there are two 
possibilities. If the 95th percentile BG is forecast below the 
upper limit of the target band hyperglycemia is satisfactorily 
controlled, and the insulin/nutrition combination is 
considered acceptable. Otherwise, neither hyper- or hypo- 
glycemia is satisfactorily controlled and the combination is 
not permitted. 
STAR maximizes performance (time in glycemic bands) with 
a minimum, clinically specified risk of mild hypoglycemia 
(5% for BG < 80mg/dL, ≈1% for BG <72mg/dL). Within this 
goal, the control determines the allowable insulin/nutrition 
combinations. Importance is placed on maximizing nutrition 
rates (Alberda et al., 2009), particularly for longer stay 
patients, but not at the risk of exacerbating hyperglycemia. 
Hence, STAR ranks allowable treatments by nutrition rate, 
ensuring the treatment with the highest enteral nutrition rate 
is selected.  
The longest measurement intervals are calculated first. If an 
acceptable treatment is found, the selected nutrition rate is 
used as a lower limit for shorter treatment intervals. This 
approach ensures treatment consistency across all 
intervention and measurement intervals to maximize 
transparency and clinical acceptance, and thus compliance 
(Chase et al., 2008a). Specifically, it ensures an intuitive 
combination of treatment options, where longer measurement 
intervals also generally yield wider stochastic forecasting 
bounds and thus more conservative (lower insulin) treatment 
choices. 
2.5  Virtual Trials 
Virtual trials were carried out to verify performance before 
clinical testing. STAR is simulated in two forms: a) 
maximum measurement interval available is chosen (“STAR 
- Max”); and b) select at maximum 2-hourly intervals when 
available (“STAR 2-hourly”) to best compare with SPRINT, 
which had a 2-hourly maximum interval. Results were 
compared to clinical SPRINT data to demonstrate 
 
Fig.1. Controller forecast schematic for BG a target range of 80 – 
145mg/dL. A BG measurement has been taken at 10hrs, and forecasts of 
BG have been generated (points A-F). The depicted distribution 
indicates the skewed nature of BG forecasts within the 5th-95th 
percentiles. 
  
     
 
improvements in performance and safety over the currently 
utilized SPRINT protocol that successfully reduced mortality 
(Chase et al., 2008b) and organ failure (Chase et al., 2010a). 
2.6 Analyses/Performance Metrics 
Performance was defined as percentage of BG within 
selected glycemic bands. Clinical effort is evaluated by BG 
measurement frequency as a surrogate (Mackenzie et al., 
2005, Aragon, 2006). Safety was defined as the incidence of 
severe (number patients with BG < 40mg/dL) and mild 
(%BG < 72mg/dL) hypoglycemia. All BG data was 
resampled hourly to provide a consistent time-basis for 
comparison across protocols with different measurement and 
intervention intervals. 
Finally, the virtual trial approach is further validated in 
comparison to results for the first 10 patients in initial STAR 
pilot clinical trials (1458 hours, 70% male, median age of 67 
[51-70], APACHE II score of 27.5 [19-30], risk of death of 
52% [31%-60%], and total mortality of 30%). All patients 
were treated for length of stay after informed consent was 
obtained. Approval for this study and use of the data was 
given by the Upper South A Ethics Committee 
(URA/10/09/069). 
3. RESULTS 
Table III shows both versions of STAR reduce the number of 
cases of severe hypoglycemia and more than halve the 
measures of mild hypoglycemia compared to SPRINT. There 
is a 79% reduction in severe hypoglycemia between STAR 2-
hourly and SPRINT showing the importance of the STAR 
approach independent of measurement interval, as both 
protocols have a 2-hour maximum interval and similar 
measurements per day. These safety gains are introduced 
with reduced clinical effort of 11.8 and 14.9 measures/day 
compared to 16.1 for SPRINT, and with equivalent or higher 
time in desired glycemic bands. Importantly, median nutrition 
rates are raised by 32% (absolute) of ACCP goal rate. Thus, 
all indications show STAR will provide global improvements 
over SPRINT in performance, safety and effort when applied 
clinically. 
Figures 2 and 3 display major behavioral differences between 
STAR and SPRINT. Each figure categorizes the 
insulin/nutrition combination selected to display relative 
frequency. Figure 2 indicates the preferred behavior of STAR 
is to modulate insulin at a higher nutrition rate, while Figure 
3 indicates SPRINT typically modulates nutrition at 
moderate, relatively constant insulin administration levels. 
This difference implies a clinical advantage when high 
nutrition input is preferred. It equally highlights that insulin 
dosage behavior is relative to carbohydrate input, showing 
importance of accounting for nutrition in AGC, which many 
published protocols do not [34]. Finally, and equally 
importantly, the most common outcome in Figure 2 is 100% 
goal feed and 0 U/hr (11% of total interventions = 1 in 9), a 
safe and effective outcome enabled by the STAR 
framework’s stochastic model-based approach that was not 
possible with SPRINT. 
 
Fig.2. STAR Nutrition/Insulin Combination Frequency 
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TABLE III 
STAR VS. SPRINT FULL COHORT SIMULATION RESULTS 
Whole cohort 
statistics 
STAR - 
Max 
STAR 2-
hourly 
SPRINT 
Data 
STAR 
clinical 
data 
# patients: 371 371 371 10 
Total hours: 40101 40006 39841 1486 
# BG measures: 19634 24218 26646 836 
Measures/day 11.8 14.9 16.1 13.5 
BG median  
[IQR] (mg/dL): 
109 
[100-120] 
109 
[100-119] 
101 
[90-115] 
109 
[99-122] 
Normoglycemia:     
% BG in 80 - 
125mg/dL 81.0 82.5 78.5 78.2 
% BG in 80 - 
145mg/dL 91.6 92.1 86.0 89.4 
Hyperglycemia:     
% BG in 145-
180mg/dL 4.69 4.59 4.45 5.63 
% BG > 
180mg/dL 1.65 1.64 2.00 2.48 
Safety:     
% BG < 80mg/dL 2.06 1.69 7.83 2.48 
% BG < 72mg/dL 0.83 0.70 2.89 1.54 
# patients < 
40mg/dL 4 3 14 0 
Interventions:     
Median insulin 
rate [IQR] (U/hr): 
2.5 
[1.5 - 4.0] 
2.5 
[1.5 - 4.0] 
3.0 
[2.0 - 4.0] 
3.0 
[1.4 - 4.5] 
Median glucose 
rate [IQR] (g/hr): 
5.0 
[2.2 - 6.4] 
5.1 
[2.3 - 6.5] 
4.1 
[1.9 - 5.6] 
4.9 
[0.0 - 6.1] 
Median glucose 
rate [IQR] (% 
goal): 
90.0 
[30-100] 
90.0 
[30-100] 
68.1 
[30-85] 
80.0 
[0.0-109] 
 
 
Fig.3. SPRINT Nutrition/Insulin Combination Frequency 
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The simulation results are supported by the initial pilot trial 
results presented in Figure 4 for the first 10 patients. The 
clinical BG results (Table III) are very similar to simulation 
results with 89.4% of BG within 80-145mg/dL and 78.2% 
BG within 80-125mg/dL. Safety has been maintained with 
1.54% of BG < 72mg/dL and no severe hypoglycemia events 
(BG < 40mg/dL). Median BG was 109mg/dL [IQR: 99.5-122 
mg/dL], which matches very closely with the location and 
spread of BG in virtual trials. 
4. DISCUSSION 
STAR virtual trials demonstrate safe, effective AGC in a 
clinically applicable fashion. Significant safety improvements 
would be likely compared to the current generation of BG 
control in Christchurch Hospital (SPRINT), which was the 
safest published protocol targeting BG ≤ 110mg/dL. Most 
significantly, only 4 patients out of 371 (1.1% by patient and 
a reduction of 71% from SPRINT) showed severe 
hypoglycemia, and, in all cases, this hypoglycemia was 
quickly resolved. Clinical applicability is strongly supported 
by the initial pilot results, with both the performance and 
safety benefits seen in virtual trials being realized in practice. 
The relatively higher enteral nutrition rate for STAR 
compared to SPRINT is likely to increase clinical acceptance. 
Higher feed is generally preferred in many cases (Alberda et 
al., 2009), despite some recent contradictory evidence 
(Casaer et al., 2011, Krishnan et al., 2003). However, STAR 
can be easily adjusted by setting nutrition administration 
goals to match any emerging evidence, and insulin rates will 
automatically modify to maintain glycemic balance. 
The comparison between STAR-Max and STAR 2-hourly 
illustrates a known trade-off between measurement rate 
(nursing workload) and patient safety. However, both provide 
quality AGC. Thus, the main impact of measurement interval 
in the STAR framework is on safety from intra-patient 
variability.  
Equally importantly, the ability of nursing staff to choose 
between measurement interval options means that an 
informed decision can be made at each BG reading. Thus, 
nurses self-manage this workload. This choice or feature is 
expected to also have a positive impact on compliance and 
acceptance. 
A notable enhancement of the model-based approach of 
STAR compared to the fixed approach in SPRINT is the 
ability to change the desired target range and other factors or 
limits. This ability has implications for the balance between 
workload, safety and nutrition. For example, raising the target 
BG range could provide increased nutrition intake at the 
expense of higher BG. Providing a wider target band may 
allow reduced workload with fewer BG measurements under 
the target-to-range scheme presented, but may result in 
increased glycemic variability within that band for which the 
clinical outcomes are not fully known. These decisions can 
be made by the attending clinical team based on their goals 
for a particular patient and assessment of current evidence. 
Hence, the framework can be directly and easily adopted and 
generalized to any clinical culture and practice, unlike 
previously published protocols. 
More importantly perhaps, STAR can thus provide the power 
to automatically balance the clinical treatment, based on 
clinical goals for each patient. It thus avoids forcing a clinic-
wide target or approach onto patients who have requirements 
outside the norm, or subjecting them to ad-hoc decisions to 
handle their particular cases. Thus, for example, different BG 
target ranges could be readily specified for different clinical 
conditions based on diagnosis and this target range could be 
updated as treatment progresses. 
5.  CONCLUSIONS 
AGC requires accounting for patient metabolic variability 
while balancing safety and workload requirements. In-silico 
results indicate the developed STAR algorithm provides a 
safe and effective method for management of glycemia. The 
model-based nature of STAR allows easy adjustment of BG 
and nutrition to match emerging clinical evidence, and 
permits individualization of treatment goals to particular 
patient outcomes. Finally, the overall framework presented is 
unique in its stochastic, risk-based approach, as well as 
completely generalizable. 
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